Structural basis for the inhibition of SARS-CoV-2 main protease by antineoplastic drug carmofur
- PMID: 32382072
- DOI: 10.1038/s41594-020-0440-6
Structural basis for the inhibition of SARS-CoV-2 main protease by antineoplastic drug carmofur
Abstract
The antineoplastic drug carmofur is shown to inhibit the SARS-CoV-2 main protease (Mpro). Here, the X-ray crystal structure of Mpro in complex with carmofur reveals that the carbonyl reactive group of carmofur is covalently bound to catalytic Cys145, whereas its fatty acid tail occupies the hydrophobic S2 subsite. Carmofur inhibits viral replication in cells (EC50 = 24.30 μM) and is a promising lead compound to develop new antiviral treatment for COVID-19.
Comment in
-
Structure of SARS-CoV-2 main protease in the apo state.Sci China Life Sci. 2021 Apr;64(4):656-659. doi: 10.1007/s11427-020-1791-3. Epub 2020 Sep 1. Sci China Life Sci. 2021. PMID: 32880863 Free PMC article. No abstract available.
References
-
- Wu, F. et al. A new coronavirus associated with human respiratory disease in China. Nature 579, 265–269 (2020). - DOI
-
- Zhou, P. et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579, 270–273 (2020). - DOI
-
- Hegyi, A. & Ziebuhr, J. Conservation of substrate specificities among coronavirus main proteases. J. Gen. Virol. 83, 595–599 (2002). - DOI
-
- Anand, K. et al. Structure of coronavirus main proteinase reveals combination of a chymotrypsin fold with an extra α-helical domain. EMBO J. 21, 3213–3224 (2002). - DOI
-
- Yang, H. et al. The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor. Proc. Natl Acad. Sci. USA 100, 13190–13195 (2003). - DOI
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous